553 related articles for article (PubMed ID: 27844283)
1. MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy.
Marques TM; Kuiperij HB; Bruinsma IB; van Rumund A; Aerts MB; Esselink RAJ; Bloem BR; Verbeek MM
Mol Neurobiol; 2017 Dec; 54(10):7736-7745. PubMed ID: 27844283
[TBL] [Abstract][Full Text] [Related]
2. Serum miR-30c-5p is a potential biomarker for multiple system atrophy.
Vallelunga A; Iannitti T; Dati G; Capece S; Maugeri M; Tocci E; Picillo M; Volpe G; Cozzolino A; Squillante M; Cicarelli G; Barone P; Pellecchia MT
Mol Biol Rep; 2019 Apr; 46(2):1661-1666. PubMed ID: 30810945
[TBL] [Abstract][Full Text] [Related]
3. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson's disease.
Uwatoko H; Hama Y; Iwata IT; Shirai S; Matsushima M; Yabe I; Utsumi J; Sasaki H
Mol Brain; 2019 May; 12(1):49. PubMed ID: 31088501
[TBL] [Abstract][Full Text] [Related]
4. The biomarker potential of cell-free microRNA from cerebrospinal fluid in Parkinsonian Syndromes.
Starhof C; Hejl AM; Heegaard NHH; Carlsen AL; Burton M; Lilje B; Winge K
Mov Disord; 2019 Feb; 34(2):246-254. PubMed ID: 30557454
[TBL] [Abstract][Full Text] [Related]
5. CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls.
Herbert MK; Eeftens JM; Aerts MB; Esselink RA; Bloem BR; Kuiperij HB; Verbeek MM
Parkinsonism Relat Disord; 2014 Jan; 20(1):112-5. PubMed ID: 24075122
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal Fluid Metabolome in Parkinson's Disease and Multiple System Atrophy.
Kwon DH; Hwang JS; Kim SG; Jang YE; Shin TH; Lee G
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163800
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy.
Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; Bloem BR; Verbeek MM
Parkinsonism Relat Disord; 2020 Jul; 76():80-84. PubMed ID: 32576494
[TBL] [Abstract][Full Text] [Related]
8. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid levels of neurofilament light chain in multiple system atrophy relative to Parkinson's disease: a meta-analysis.
Hu X; Yang Y; Gong D
Neurol Sci; 2017 Mar; 38(3):407-414. PubMed ID: 27896490
[TBL] [Abstract][Full Text] [Related]
10. Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms.
Santaella A; Kuiperij HB; van Rumund A; Esselink RAJ; van Gool AJ; Bloem BR; Verbeek MM
BMC Neurol; 2020 Jan; 20(1):26. PubMed ID: 31952511
[TBL] [Abstract][Full Text] [Related]
11. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
[TBL] [Abstract][Full Text] [Related]
13. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
14. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson's disease patients.
Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Tang BS; Wang CY
J Clin Neurosci; 2019 Dec; 70():198-201. PubMed ID: 31492481
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease.
Folke J; Rydbirk R; Løkkegaard A; Hejl AM; Winge K; Starhof C; Salvesen L; Pedersen LØ; Aznar S; Pakkenberg B; Brudek T
Parkinsonism Relat Disord; 2021 Jun; 87():98-104. PubMed ID: 34020303
[TBL] [Abstract][Full Text] [Related]
16. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
18. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
Gui Y; Liu H; Zhang L; Lv W; Hu X
Oncotarget; 2015 Nov; 6(35):37043-53. PubMed ID: 26497684
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease.
Abdo WF; De Jong D; Hendriks JC; Horstink MW; Kremer BP; Bloem BR; Verbeek MM
Mov Disord; 2004 May; 19(5):571-9. PubMed ID: 15133823
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid cytokines in multiple system atrophy: A cross-sectional Catalan MSA registry study.
Compta Y; Dias SP; Giraldo DM; Pérez-Soriano A; Muñoz E; Saura J; Fernández M; Bravo P; Cámara A; Pulido-Salgado M; Painous C; Ríos J; Martí MJ;
Parkinsonism Relat Disord; 2019 Aug; 65():3-12. PubMed ID: 31178335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
